Últimas noticias sobre Agilon Health (NYSE:AGL) Bolsa

AGILON HEALTH INC

Agilon Health

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAMI

ACEL

AXON

CDNA

CLIK

ENVB

FLYW

HCTI

ICCT

LBTYK

LMND

NAMS

PITA

PRCH

SMCI

ZoomInfo sorprende con resultados mejores de lo esperado y sus acciones suben un 19,6%. Descubre qué otras acciones se están moviendo hoy.

Acciones de ZoomInfo se disparan un 20%; 20 acciones que se están moviendo en el premercado de EE.UU.

Agilon Health Inc

T2 Metals Corp

Adventure Gold - United States Dollar

AUSTRAL GOLD LTD ORD by Austral Gold Ltd.

Austral Gold Ltd

ANGELALIGN TECH INC by Angelalign Technologies Inc.

Angelalign Technology Inc

AGL Energy Ltd

AGILITY REAL EST NEW by Agility Real Estate Inc.

Agility Capital Holding Inc

ANGEL TELECOM CORP by Angel Telecom Corp.

AgileThought Inc

ATLANTIS GLORY INC by Atlantis Glory Inc.

Atlantis Glory Inc

<p>Cryptocurrencies are trading lightly up on Tuesday morning as the Fear &amp; Greed Index remains in neutral territory.</p>
<p><figure class="wp-block-table"><br />
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$105,370</td>
<td>+0.90%</td>
</tr>
<tr>
<td><strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,614.6</td>
<td>+5.1%</td>
</tr>
<tr>
<td><strong>Solana</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$161.4</td>
<td>+4.5%</td>
</tr>
<tr>
<td><strong>XRP </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.20</td>
<td>+2.9%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1956</td>
<td>+2.9%</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001320</td>
<td>+3.3%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume increasing by 72.1% and 127.8%, respectively. BTC's daily active addresses went up by 12%. Ethereum's exchanges netflows surged by 4,563.6% in a single day.</li>
<li>Coinglass data shows 76,813 traders were liquidated in the past 24 hours for $195.07 million.</li>
<li>SoSoValue data shows a $267.5 million net outflow out of spot Bitcoin ETFs. Spot Ethereum ETFs saw a net intflow of $78.2 million.</li>
</ul>
<p><strong>Trader Notes</strong>: Cypto trader Jelle <a href="https://x.com/CryptoJelleNL/status/1929809082812187040">noted</a> that key weekly resistance now acts as support. If Bitcoin closes the week strong, $140,000 could be the next leg. </p>
<p>Altcoin Sherpa believes BTC has likely formed a solid low. </p>
<p>While a clean break above $107,000 may not happen immediately, a short-term bounce to $109,000–$110,000 is expected.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">All in all, this looks like a pretty good low formed for <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a>. Not sure if it truly breaks that 107k region on this go but I think that this bounces to at least the 109-110ks at a minimum first (even if we&#39;re going lower). Still bullish in the short term but watching <a href="https://t.co/a24uOxlnj9">pic.twitter.com/a24uOxlnj9</a></p>
<p>&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1929722760953319432?ref_src=twsrc%5Etfw">June 3, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Crypto trader Michael van de Poppe predicts Ethereum is "poised for a significant upward breakout."</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> appears poised for a significant upward breakout. <a href="https://t.co/OjBE6h87pr">pic.twitter.com/OjBE6h87pr</a></p>
<p>&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1929843753851732006?ref_src=twsrc%5Etfw">June 3, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Bluntz Capital <a href="https://x.com/Bluntz_Capital/status/1929664204925292694">argues</a> that altcoin season is brewing. When buying returns, meme coins typically outperform, driven more by hype than fundamentals.</p>
<p>Trader Tardigrade noted that Dogecoin is mirroring its August–October 2024 setup. A massive surge may be near.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> repeats previous price action &#x1f525;<br />A massive surge is set to go &#x1f680;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/xdsN4zzcMx">pic.twitter.com/xdsN4zzcMx</a></p>
<p>&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1929825903779238271?ref_src=twsrc%5Etfw">June 3, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>For Solana, Crypto Bully <a href="https://x.com/BullyDCrypto/status/1929696282030883291">stated</a> that he is not buying yet, but a tap into $143 support or a reclaim above $160 would be an opportunity.</p>
<p>The trader is willing to pay a premium to long a strong reclaim of the $160s, targeting moves to $180 and then $200.</p>
<p><strong>Read Next:  </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45727395/tom-lee-predicts-bitcoin-to-hit-250000-by-end-of-2025-3m-long-term">Tom Lee Predicts Bitcoin To Hit $250,000 By End Of 2025, $3M Long Term</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Edge Higher As Traders Maintain Bullish Outlook

<p>Raytheon, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, has been awarded a $536 million contract from the U.S. Navy for the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440248-1&amp;h=3865036397&amp;u=https%3A%2F%2Fwww.rtx.com%2Fraytheon%2Fwhat-we-do%2Fsea%2Fspy6-radars&amp;a=SPY-6+family+of+radars">SPY-6 family of radars</a>. The contract is a follow-on to the previously awarded <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440248-1&amp;h=255970049&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fus-navy-awards-raytheon-114-million-contract-for-spy-6-integration-and-support-300769237.html&amp;a=Integration+and+Production+Support+contract">Integration and Production Support contract</a> and includes upgrading Flight IIA destroyers with the SPY-6(V)4 variant.</p>
<p>Under the sole source award, Raytheon will provide continued support for the SPY-6 family of radars through training, engineering services, ship installation, integration and testing, as well as software upgrades to enhance radar capabilities.</p>
<p>"SPY-6 is the most advanced radar in the U.S. naval fleet, providing ships a new level of defense against evolving threats," said Barbara Borgonovi, president of Naval Power at Raytheon. "This contract highlights the essential role of this technology in supporting the U.S. Navy's technology roadmap for several decades to come."</p>
<p>SPY-6 is now installed on two new U.S. Navy ships, with three additional ships slated for installation and undergoing various stages of testing in 2025. Over the next decade, SPY-6 is expected to be deployed on more than 60 U.S. Navy ships, enhancing defense against air, surface, and ballistic threats.</p>


Contracts

Raytheon, an RTX Business Announces It Has Been Awarded A $536M Contract From The U.S. Navy For The Spy-6 Family Of Radars

Management

Integral Ad Science Appoints Alpana Wegner As CFO, Succeeding Jill Putman, Effective June 10, 2025

<p>JP Morgan  analyst Cory Carpenter   maintains Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) with a Overweight and raises the price target from $36 to $38.</p>


Price Target

Analyst Ratings

XMTR

JP Morgan Maintains Overweight on Xometry, Raises Price Target to $38

<p><strong>Vivakor, Inc&#8217;s </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIVK#NASDAQ">VIVK</a>)<strong> </strong>announced Tuesday that its growth strategy is anchored in the Permian and Eagle Ford Basins, where the company is positioned to expand its <a href="https://www.benzinga.com/topic/crude-oil" target="_blank" rel="noreferrer noopener">integrated crude oil</a> storage, logistics, and marketing value chains.</p>
<p>Vivakor said it owns and operates 10 strategically located pipeline injection stations in the core Permian Basin in Texas and New Mexico.</p>
<p>These facilities receive and aggregate crude oil transported by truck from production wells, throughputting volumes into interstate crude oil pipelines that include Centurion (Lotus), Plains Basin Pipeline (PAA), and the West Texas System (EPD).</p>
<p><em><strong>Also Read: <a href="https://www.benzinga.com/trading-ideas/dividends/25/05/45691981/exclusive-vivakor-announces-special-stock-dividend" target="_blank" rel="noreferrer noopener">Vivakor Announces Special Stock Dividend</a></strong></em></p>
<p>James Ballengee, Vivakor Chairman and CEO, said its facilities in the Permian enabled it to support increasing volumes from upstream operators, enhance crude blending and compression efficiency, and ultimately drive revenue growth and operating leverage as activity scales.</p>
<p>Ballengee said the Permian continues to be the biggest contributor to U.S.&nbsp;crude oil and NGL production, supporting international and domestic energy demand. Consistent drilling, quantities produced, and barrels brought to key markets bolstered its revenues and business model.</p>
<p>Vivakor&#8217;s infrastructure directly supports its broader strategy to deliver vertically integrated services in one of the world&#8217;s most productive oil regions.&nbsp; With the Permian accounting for over 40% of total U.S. oil output, Vivakor&#8217;s expanded operations give it a front-row seat to the sector&#8217;s next growth cycle.</p>
<p><strong>Price Action:&nbsp;</strong>VIVK stock closed lower by 6.14% at $1.07 on Monday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/bonds/25/06/45723708/rivian-stock-goes-red-after-offering-1-25-billion-green-bond-to-refinance-2026-debt" target="_blank" rel="noreferrer noopener"><em><strong>Rivian Stock Goes Red After Offering $1.25 Billion Green Bond To Refinance 2026 Debt</strong></em></a></li>
</ul>



Market-Moving Exclusives

Exclusives

VIVK

EXCLUSIVE: Vivakor Bets On Permian Boom With 10 Crude Hubs

<p>In the latest quarter, 9 analysts provided ratings for Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Protagonist Therapeutics, revealing an average target of $72.56, a high estimate of $80.00, and a low estimate of $54.00. This current average has increased by 8.66% from the previous average price target of $66.78. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748952088_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Protagonist Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Yun Zhong</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Protagonist Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Protagonist Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Protagonist Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Protagonist Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PTGX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Protagonist Therapeutics analyst ratings.</strong></a></p>
<h2>Get to Know Protagonist Therapeutics Better</h2>
<p>Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.</p>
<h3>Protagonist Therapeutics: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Protagonist Therapeutics's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-88.89%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Protagonist Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-41.15%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Protagonist Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-1.71%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Protagonist Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1.57%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Protagonist Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.02</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PTGX

9 Analysts Assess Protagonist Therapeutics: What You Need To Know

<p>In the preceding three months, 11 analysts have released ratings for Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $5.75, a high estimate of $9.00, and a low estimate of $4.00. Experiencing a 15.44% decline, the current average is now lower than the previous average price target of $6.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748952079_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Bumble's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Kunal Madhukar</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.80</td>
<td>$6.80</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$4.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Nathan Feather</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.50</td>
<td>$6.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Nathan Feather</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bumble. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bumble compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Bumble's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bumble's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BMBL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Bumble analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Bumble: A Closer Look</h2>
<p>Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.</p>
<h3>Bumble: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Bumble faced challenges, resulting in a decline of approximately <strong>-7.72%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Bumble's net margin is impressive, surpassing industry averages. With a net margin of <strong>5.44%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bumble's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.64%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Bumble's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.53%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.77</strong>.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BMBL

Breaking Down Bumble: 11 Analysts Share Their Views

<p>JP Morgan  analyst Cory Carpenter   maintains ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Overweight and raises the price target from $63 to $85.</p>


JP Morgan Maintains Overweight on ODDITY Tech, Raises Price Target to $85

<p>In the last three months, 5 analysts have published ratings on Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $73.2, along with a high estimate of $85.00 and a low estimate of $60.00. A 9.63% drop is evident in the current average compared to the previous average price target of $81.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748952059_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Credo Technology Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Thomas O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$69.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Credo Technology Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Credo Technology Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Credo Technology Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Credo Technology Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRDO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Credo Technology Group analyst ratings.</strong></a></p>
<h2>Discovering Credo Technology Group: A Closer Look</h2>
<p>Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.</p>
<h3>Breaking Down Credo Technology Group's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Credo Technology Group's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately <strong>154.44%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Credo Technology Group's net margin is impressive, surpassing industry averages. With a net margin of <strong>21.75%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Credo Technology Group's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.95%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Credo Technology Group's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.32%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Credo Technology Group's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CRDO

What Analysts Are Saying About Credo Technology Group Stock

<p>Throughout the last three months, 4 analysts have evaluated TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $116.0, with a high estimate of $130.00 and a low estimate of $104.00. Observing a 9.43% increase, the current average has risen from the previous average price target of $106.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748952044_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of TransMedics Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$104.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to TransMedics Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of TransMedics Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of TransMedics Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of TransMedics Group's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TMDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on TransMedics Group analyst ratings.</strong></a></p>
<h2>About TransMedics Group</h2>
<p>TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.</p>
<h3>TransMedics Group: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> TransMedics Group's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>48.21%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> TransMedics Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>17.89%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> TransMedics Group's ROE excels beyond industry benchmarks, reaching <strong>10.38%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> TransMedics Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.13%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> TransMedics Group's debt-to-equity ratio surpasses industry norms, standing at <strong>1.95</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TMDX

4 Analysts Have This To Say About TransMedics Group

<p>Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $187.36, a high estimate of $230.00, and a low estimate of $147.00. Observing a 0.05% increase, the current average has risen from the previous average price target of $187.27. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748952029_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$183.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$179.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Jazz Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Jazz Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Jazz Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Jazz Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Discovering Jazz Pharmaceuticals: A Closer Look</h2>
<p>Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.</p>
<h3>Jazz Pharmaceuticals: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Jazz Pharmaceuticals faced challenges, resulting in a decline of approximately <strong>-0.46%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Jazz Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-10.31%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Jazz Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.24%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Jazz Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.79%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Jazz Pharmaceuticals's debt-to-equity ratio is below the industry average at <strong>1.3</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


JAZZ

The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts

<p>Across the recent three months, 23 analysts have shared their insights on Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $38.04, a high estimate of $45.00, and a low estimate of $28.00. Observing a downward trend, the current average is 9.15% lower than the prior average price target of $41.87. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1748952021_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Pinterest by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$34.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pinterest. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pinterest compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Pinterest's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Pinterest's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PINS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Pinterest analyst ratings.</strong></a></p>
<h2>Get to Know Pinterest Better</h2>
<p>Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.</p>
<h3>Pinterest: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Pinterest showcased positive performance, achieving a revenue growth rate of <strong>15.54%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> Pinterest's net margin excels beyond industry benchmarks, reaching <strong>1.04%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Pinterest's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.19%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.17%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Pinterest's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.03</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PINS

Demystifying Pinterest: Insights From 23 Analyst Reviews

EXCLUSIVE: Vivakor Tells Benzinga Co. Strengthens Permian Presence With 10 Pipeline Stations Fueling Revenue And Margin Expansion

<p>JP Morgan  analyst Cory Carpenter   maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Overweight and raises the price target from $75 to $85.</p>


ROKU

JP Morgan Maintains Overweight on Roku, Raises Price Target to $85

<p>JP Morgan  analyst Cory Carpenter   maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Overweight and raises the price target from $80 to $100.</p>


RBLX

JP Morgan Maintains Overweight on Roblox, Raises Price Target to $100

<p>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("<strong>Quantum BioPharma</strong>"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces its response to information about certain stock trading platforms as well as misinformation being circulated on certain social media channels. Certain stock trading platforms mistakenly have the Quantum BioPharma name changed to Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) after the news release was issued on May 29, 2025. Quantum BioPharma has not changed its name.</p>


CSE:QNTM

QNTM

Quantum BioPharma Announces Clarification That It Has Not Changed Its Name To Unbuzzd Wellness Inc

<p>JP Morgan  analyst Cory Carpenter   downgrades Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) from Neutral to Underweight and maintains the price target from $5 to $5.</p>


Downgrades

JP Morgan Downgrades Bumble to Underweight, Maintains Price Target to $5

<p>Cloudflare (NET) is currently navigating the 7th Phase of its 18-Phase Adhishthana Cycle. While the structure remains constructive, investors expecting a breakout may need to exercise patience as the real move may not unfold until March 2026. Here's a detailed look at why.</p>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="675" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana-.png" alt="Fig.1 Cloudflare's Adhishthana Phases (Source: Adhishthana.com)" class="wp-image-13784" style="width:679px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana--300x169.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana--1024x576.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03105458/Cloudflare-Adhishthana--768x432.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /></figure></p>
<h3 class="wp-block-heading"><strong>How Has Cloudflare Aligned With the Adhishthana Principles So Far?</strong></h3>
<p>On the weekly chart, Cloudflare has displayed a strong 94% alignment with the Adhishthana Principles, our proprietary cyclical framework that combines quantitative signals with behavioral archetypes. Here are some key highlights from past phases of the current cycle:</p>
<h4 class="wp-block-heading"><strong>Phase 2: The Rally of Buddhi</strong></h4>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1098" height="1000" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana-.png" alt="Fig.2 Cloudflare Stock Phase 2 (Source: Adhishthana.com)" class="wp-image-13777" style="width:486px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana-.png 1098w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana--300x273.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana--1024x933.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104138/Cloudfare-Phase-2-Adhishthana--768x699.png 768w" sizes="(max-width: 1098px) 100vw, 1098px" /><figcaption class="wp-element-caption">Fig.2 Cloudflare Stock Phase 2 (Source: Adhishthana.com)</figcaption></figure></p>
<p>Cloudflare traded in a tight consolidation for exactly 37 bars, in line with what the framework prescribes. Following that, it broke out and rallied by ~216%, marking a textbook Rally of Buddhi.</p>
<h4 class="wp-block-heading"><strong>Phase 3: Yajya Formation</strong></h4>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="686" height="636" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104235/Cloudfare-Phase-3-Adhishthana-.png" alt="Fig.3 Cloudflare Stock Phase 3(Source: Adhishthana.com)" class="wp-image-13778" style="width:471px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104235/Cloudfare-Phase-3-Adhishthana-.png 686w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104235/Cloudfare-Phase-3-Adhishthana--300x278.png 300w" sizes="(max-width: 686px) 100vw, 686px" /><figcaption class="wp-element-caption">Fig.3 Cloudflare Stock Phase 3 (Source: Adhishthana.com)</figcaption></figure></p>
<p>During Phase 3, Cloudflare formed a classic <em>Yajya Formation</em>, a distinctive Adhishthana hand-arc structure. It rallied slightly, formed a smooth arc, and then corrected sharply, completing the behavioral cycle of this phase precisely.</p>
<h4 class="wp-block-heading"><strong>Phase 6: Discovery of Nirvana</strong></h4>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1014" height="710" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104258/Cloudfare-Phase-6-Adhishthana.png" alt="Fig.4 Cloudflare Stock Phase 6 (Source: Adhishthana.com)" class="wp-image-13779" style="width:554px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104258/Cloudfare-Phase-6-Adhishthana.png 1014w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104258/Cloudfare-Phase-6-Adhishthana-300x210.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104258/Cloudfare-Phase-6-Adhishthana-768x538.png 768w" sizes="(max-width: 1014px) 100vw, 1014px" /><figcaption class="wp-element-caption">Fig.4 Cloudflare Stock Phase 6 (Source: Adhishthana.com)</figcaption></figure></p>
<p>After 24 bars of trading in Phase 6, Cloudflare formed its Level of Nirvana at $85.13. This level now acts as both a valuation barometer and a potential price magnet during corrections throughout the cycle.</p>
<h3 class="wp-block-heading"><strong>What's Unfolding in Cloudflare&#8217;s 7th Phase?</strong></h3>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="910" height="608" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104354/Cloudfare-Phase-7.png" alt="Fig.5 Cloudflare Stock Phase 7 (Source: Adhishthana.com)" class="wp-image-13780" style="width:537px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104354/Cloudfare-Phase-7.png 910w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104354/Cloudfare-Phase-7-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/03104354/Cloudfare-Phase-7-768x513.png 768w" sizes="(max-width: 910px) 100vw, 910px" /><figcaption class="wp-element-caption">Fig.5 Cloudflare Stock Phase 7 (Source: Adhishthana.com)</figcaption></figure></p>
<p>Phase 7 brought the expected &#8220;Fall of Artha and Artharthi&#8221;, a behavioral correction designed to flush out speculative hands and reset the valuation. Cloudflare dropped nearly 48% shortly after entering the phase, accompanied by exactly seven red bars, which is highly consistent with Adhishthana principles.</p>
<p>Interestingly, the correction found support just above the Nirvana level at $85.13. Since then, the stock has rebounded strongly, nearly reclaiming the Phase 7 entry high around $177.37. However, a decisive breakout above this level may remain elusive for now.</p>
<h3 class="wp-block-heading"><strong>Why Cloudflare&#8217;s Breakout Might Be Delayed</strong></h3>
<p>While momentum has returned, Cloudflare remains in Phase 7, which is not typically when major breakouts occur. According to Adhishthana Principles, the supreme move is expected during Phase 9, set to begin on 2 March 2026.</p>
<p>Until then, the stock may continue to form what we call the <em>Cakra</em>, or &#8220;Arc&#8221;, a bullish rising channel with a curve. The true breakout is more likely to occur after the completion of this structure, when Phase 9 begins.</p>
<h3 class="wp-block-heading"><strong>Investor Takeaway</strong></h3>
<p>Cloudflare is building a constructive base within its Phase 7 structure, and its adherence to Adhishthana Cyclical Principles has been striking. For long-term investors:</p>
<ul class="wp-block-list">
<li>Accumulation near or just above the Nirvana level ($85.13) could be prudent for those seeking deep-cycle opportunities.<br /></li>
<li>Chasing strength near current highs may not be optimal, as a decisive breakout is not expected before Phase 9 begins in March 2026.<br /></li>
<li>Watch the Cakra closely; if the bullish arc remains intact, the setup continues to improve. However, if the Cakra breaks to the downside, it could attract significant selling pressure.</li>
</ul>
<p>The stock remains a buy-on-dip candidate, with a stronger case for a breakout emerging in its Phase 9.&nbsp;</p>


Equities

Technicals

Opinion

Signals

Cloudflare Strengthening, Yet Breakout Unlikely Until 2026

<p>During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.</p>
<p>Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.</p>
<p>Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.</p>
<h3 class="wp-block-heading"><strong>Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>)</strong></h3>
<ul class="wp-block-list">
<li><strong>Dividend Yield:</strong> 6.73%</li>
<li><strong>Barclays </strong>analyst Gaurav Jain maintained an Underweight rating and raised the price target from $46 to $49 on May 2, 2025. This analyst has an accuracy rate of 66%.</li>
<li><strong>Stifel </strong>analyst Matthew Smith maintained a Buy rating and raised the price target from $60 to $63 on April 30, 2024. This analyst has an accuracy rate of 60%.</li>
<li><strong>Recent News:</strong> On April 29, Altria Group posted upbeat quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MO <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603">news</a>. </li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603"><img loading="lazy" decoding="async" width="912" height="858" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074100/image-26.png" alt="" class="wp-image-936503" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074100/image-26.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074100/image-26-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074100/image-26-768x723.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)</strong></h3>
<ul class="wp-block-list">
<li><strong>Dividend Yield:</strong> 6.15%</li>
<li><strong>Wells Fargo </strong>analyst Chris Carey maintained an Equal-Weight rating and cut the price target from $27 to $23 on June 2, 2025. This analyst has an accuracy rate of 63%.</li>
<li><strong>JP Morgan </strong>analyst Ken Goldman maintained a Neutral rating and cut the price target from $26 to $25 on May 6, 2025. This analyst has an accuracy rate of 78%.</li>
<li><strong>Recent News:</strong> On May 1, Hometown Food Company announced plans to acquire Chef Boyardee Brand from Conagra Brands for $600 million.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest CAG <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603">news </a></li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603"><img loading="lazy" decoding="async" width="922" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074137/image-27.png" alt="" class="wp-image-936504" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074137/image-27.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074137/image-27-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074137/image-27-768x708.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure></p>
<h3 class="wp-block-heading"><strong>Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)</strong></h3>
<ul class="wp-block-list">
<li><strong>Dividend Yield: </strong>4.80%</li>
<li><strong>Guggenheim </strong>analyst Robert Drbul maintained a Buy rating and cut the price target from $155 to $115 on May 27, 2025. This analyst has an accuracy rate of 62%.</li>
<li><strong>Telsey Advisory Group </strong>analyst Joseph Feldman downgraded the stock from Outperform to Market Perform and cut the price target from $130 to $110 on May 22, 2025. This analyst has an accuracy rate of 65%.</li>
<li><strong>Recent News: </strong>On May 21, Target registered adjusted earnings per share of $1.30, missing analysts' consensus estimate of $1.64. Quarterly sales of $23.85 billion (down 2.8% year over year) missed the Street view of $24.32 billion.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest TGT <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603">news </a></li>
</ul>
<p><figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0603"><img loading="lazy" decoding="async" width="926" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074751/image-28.png" alt="" class="wp-image-936511" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074751/image-28.png 926w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074751/image-28-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03074751/image-28-768x703.png 768w" sizes="(max-width: 926px) 100vw, 926px" /></a></figure></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read More: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/cannabis/25/06/45719976/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-and-telecom-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech And Telecom Stocks Delivering High-Dividend Yields</a></strong></li>
</ul>
<p>Photo via Shutterstock</p>


Dividends

Wall Street's Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields

<p>JP Morgan  analyst Doug Anmuth   upgrades Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) from Neutral to Overweight and raises the price target from $35 to $40.</p>


Upgrades

JP Morgan Upgrades Pinterest to Overweight, Raises Price Target to $40

Press Releases

agilon health Reports ACO REACH Model Results for 2023 Performance Year

Legal

Agilon Health, Inc, B. Riley Financial, Target Corporation, and Getty Images Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of agilon health, inc. (NYSE: AGL) and Encourages Long-Term Investors to Contact the Firm

agilon health to Participate in TD Cowen's 45th Annual Health Care Conference

agilon health Reports Fourth Quarter and Full Year Fiscal 2024 Results

agilon health Sets Date to Report First Quarter 2025 Financial Results

agilon health to Participate in BofA Securities 2025 Health Care Conference

agilon health Reports First Quarter 2025 Results

agilon health to Participate in Bernstein's 41st Annual Strategic Decisions Conference

GETY

RILY

Addus HomeCare Corporation - Common Stock

Addus HomeCare

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Agilon Health

Noticias

Últimas noticias sobre Agilon Health (NYSE:AGL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL